
SCARD Pool report for 01-01-2006 to 31-12-2006

Participants	Doctors	18	
	Patients	474	
Specimens	New lesions	677	83.79%
	Previously biopsied lesions	131	16.21%
	Total lesions	808	100.00%

Breakdown of new versus previously biopsied specimens



Percentage of new lesions tested which were malignant	44.43%
Percentage of Definitively excised lesions that were malignant	52.27%
Lesions tested to find one melanoma (NNT)	22.63
Percentage of lesions tested for NMSC which were NMSC	60.63%
Ratio of New BCCs : New Melanomas	20:1

Accuracy

Diagnostic sensitivity

Melanomas	62.50% of 8
All NMSC	95.14% of 288
BCCs	94.27% of 157
SCCs	66.67% of 129

Positive predictive value

Melanomas	25.00% of 20
All NMSC	78.51% of 349
BCCs	42.41% of 349
SCCs	68.25% of 126

Adequacy

Percentage of definitively managed malignant cases where surgical margins were adequate


BCC	94.39% of 107
IEC/Bowens disease	100.00% of 24
SCC	91.84% of 49
Keratoacanthoma	100.00% of 3
Melanoma - in situ	100.00% of 6
Melanoma - invasive	75.00% of 4
Melanoma - invasive > 1mm	0% of 0
Other malignant	100.00% of 1

© 2026 SCARD Systems Pty Ltd

Lesion Breakdown

Histological Diagnosis

BCC (unspecified type)	75	10.98%
BCC - Superficial	32	4.69%
BCC - Nodular/Solid	35	5.12%
BCC - Aggressive	15	2.20%
IEC/Bowens disease	42	6.15%
SCC	84	12.30%
Keratoacanthoma	3	0.44%
Pinkus Fibroepithelioma	0	0%
Merkel cell tumour	0	0%
Other malignant	1	0.15%
NMSC Metastasis	0	0%
Melanoma - in situ	6	0.88%
Melanoma - invasive	2	0.29%
Melanoma - invasive > 1mm	0	0%
Melanoma - metastasis	0	0%
MELTUMP	1	0.15%
Naevus - other	83	12.15%
Naevus - dysplastic/Clark	38	5.56%
Naevus - blue	2	0.29%
Naevus - Spitz/Reed	2	0.29%
Naevus - Compound	0	0%
Solar keratosis	47	6.88%
Solar lentigo	9	1.32%
Seborrhoeic keratosis	69	10.10%
Lentigo Simplex	0	0%
Lichenoid keratosis (LPLK)	5	0.73%
Dermatofibroma	8	1.17%
Sebaceous gland hyperplasia	2	0.29%
Benign cyst	14	2.05%
Other benign	89	13.03%
Histology Pending	6	0.88%



© 2026 SCARD Systems Pty Ltd

Procedures

Definitive Surgical Management used to exclude melanoma

Ellipse	89	94.68%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	4	4.26%
Shave/Saucerisation	0	0%
Curettage & Cautery	1	1.06%
Liquid N2 freeze/thaw	0	0%
PDT	0	0%
Imiquimod	0	0%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	0	0%
Other	0	0%

Biopsy used to exclude melanoma

Punch - sample	10	11.49%
Shave - sample	12	13.79%
Incisional	1	1.15%
Punch - removal	5	5.75%
Shave - removal	6	6.90%
Excisional	53	60.92%
Curettage	0	0%
Other	0	0%

Breakdown of definitive management procedures for malignant conditions

Ellipse	207	66.99%
Flap	11	3.56%
Graft - SSG	0	0%
Graft - FTSG	1	0.32%
No Closure	0	0%
Shave/Saucerisation	0	0%
Curettage & Cautery	11	3.56%
Liquid N2 freeze/thaw	4	1.29%
PDT	1	0.32%
Imiquimod	17	5.50%
5 FU cream	0	0%
GP referral	1	0.32%
Specialist referral	55	17.80%
Other	0	0%

Breakdown of definitive management procedures for benign conditions

Ellipse	130	78.31%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	6	3.61%
Shave/Saucerisation	0	0%
Liquid N2 freeze/thaw	6	3.61%
5 FU cream	6	3.61%
GP referral	0	0%
Specialist referral	1	0.60%
Other	0	0%

© 2026 SCARD Systems Pty Ltd

Procedures (continued)


Percentage of procedures/closures that were complex

Complex Closures	0% of 207
Complex Closures (inc Curettage & Cautery)	0% of 224

Locations

Breakdown of melanomas by location and percentage melanomas of total lesions at that location

Nose	0	0% of 32
Lip	0	0% of 14
Ear	0	0% of 20
Eyelid	0	0% of 3
Other face	0	0% of 53
Scalp	0	0% of 15
Neck	1	2.94% of 34
Shoulder	2	5.88% of 34
Chest	0	0% of 47
Abdomen	0	0% of 18
Genitalia	0	0% of 0
Back	2	1.80% of 111
Buttock	1	11.11% of 9
Arm	0	0% of 30
Forearm	0	0% of 41
Hand Dorsal	0	0% of 37
Hand Palmar	0	0% of 0
Finger Dorsal	0	0% of 7
Finger Nail	0	0% of 0
Finger Palmar	0	0% of 1
Thigh	2	6.06% of 33
Leg	0	0% of 68
Foot Dorsal	0	0% of 10
Foot Plantar	0	0% of 8
Toe Dorsal	0	0% of 3
Toe Nail	0	0% of 0
Toe Plantar	0	0% of 0
Palm Or Sole	0	0% of 0



© 2026 SCARD Systems Pty Ltd